Adare Pharmaceuticals: Optimizing therapeutic performance. Creating new possibilities for patients.
When it comes to optimizing the therapeutic performance of oral drugs, customizing drug release profiles can provide a number of benefits, including improved efficacy, enhanced safety, and reduced dosing frequency. Adare has several proprietary technologies that can be used to customize drug release profiles and optimize the therapeutic performance of oral drugs.
When it comes to optimizing the therapeutic performance of oral drugs, customizing drug release profiles can provide a number of benefits, including improved efficacy, enhanced safety, and reduced dosing frequency.
Adare has several proprietary technologies that can be used to customize drug release profiles and optimize the therapeutic performance of oral drugs.
Diffucaps® Customized Release Technology
This technology has the flexibility to incorporate functional, release-controlling polymers or protective coatings onto drug-layered cores, granules, or crystals. This multiparticulate system provides sophisticated control of drug delivery and optimizes release profiles for single drugs and drug combinations.
Examples of customized release particles
Eurand Minitabs® Controlled Release Technology
This technology combines the simplicity of a tablet formulation with the flexibility of multiparticulate dosage forms with high drug-loading capability. A significant advantage of Eurand Minitabs® technology is the ability for the patient or caregiver to open the capsule and sprinkle the contents on soft foods or add to a liquid. This is especially helpful for the pediatric patient, the elderly patient, or anyone who has difficulty swallowing.
With a broad range of proprietary technologies, Adare can help you overcome formulation challenges. To learn more, contact Lisa.Miller@adarepharma.com or visit www.AdarePharma.com .
©2015 Adare Pharmaceuticals, Inc.
Drug Solutions Podcast: Novel Drug Delivery Approaches: Refining AAV Vector Deliveries
May 30th 2025In this podcast episode, we discuss novel approaches to drug delivery, specifically regarding adeno-associated virus (AAV) vectors, as viewed by two industry experts who recently exhibited at the annual ASGCT meeting.
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
A Novel, Enhanced, and Sustainable Approach to Audit Trail Review
July 4th 2025Eli Lilly and Company developed an innovative and sustainable approach to audit trail review (ATR) aimed at reducing the ATR burden while adhering to regulatory expectations and data integrity (DI) principles. The process has transformed employees' understanding of ATR and complemented the DI by design approach, leading to better system designs that meet expected controls and reduce non-value-added data reviews.
